Kexing Biopharm’s Biologics License Application for Long-Acting G-CSF Candidate GB-K02 Accepted for ReviewSAN DIEGO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kexing Biopharm (688136.SH) recently announced that it has received a Notice of Acceptance from China’s National Medical Products Administration (NMPA) for the biologics license application (BLA) for GB-K02, its self-developed PEGylated human granulocyte colony-stimulating factor (G-CSF) injection.
